An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease
ABSTRACT: Objectives: The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time–kill studies. Methods: We determined the MICs to 13 drugs against the Mk...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716521002848 |
| _version_ | 1818284098594013184 |
|---|---|
| author | Shashikant Srivastava Jotam G. Pasipanodya Scott K. Heysell Gunavanthi D. Boorgula Tawanda Gumbo Pamela J. McShane Julie V. Philley |
| author_facet | Shashikant Srivastava Jotam G. Pasipanodya Scott K. Heysell Gunavanthi D. Boorgula Tawanda Gumbo Pamela J. McShane Julie V. Philley |
| author_sort | Shashikant Srivastava |
| collection | DOAJ |
| description | ABSTRACT: Objectives: The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time–kill studies. Methods: We determined the MICs to 13 drugs against the Mkn standard laboratory strain ATCC 12478 and 20 clinical isolates and performed time–kill studies with 18 drugs from different classes using the standard laboratory strain of Mkn. The β-lactam antibiotics were tested with or without the combination of the β-lactamase inhibitor avibactam. An inhibitory sigmoid Emax model was used to describe the relationship between drug concentrations and bacterial burden. Results: Among the 13 tested drugs in the MIC experiments, the lowest MIC was recorded for bedaquiline. Among the 18 drugs used in the time–kill studies, maximum kill with cefdinir, tebipenem, clarithromycin, azithromycin, moxifloxacin, levofloxacin, tedizolid, bedaquiline, pretomanid and telacebac was greater than that for some of the drugs (isoniazid, rifampicin and ethambutol) used in standard combination therapy. Conclusion: We report preclinical data on the efficacy and potency of drugs that can potentially be repurposed to create a safe, effective and likely shorter-duration regimen for the treatment of Mkn pulmonary disease. |
| first_indexed | 2024-12-13T00:47:24Z |
| format | Article |
| id | doaj.art-05bd52f57d154d76bdd4964e18f6a48a |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-12-13T00:47:24Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-05bd52f57d154d76bdd4964e18f6a48a2022-12-22T00:05:00ZengElsevierJournal of Global Antimicrobial Resistance2213-71652022-03-01287177An overview of drugs for the treatment of Mycobacterium kansasii pulmonary diseaseShashikant Srivastava0Jotam G. Pasipanodya1Scott K. Heysell2Gunavanthi D. Boorgula3Tawanda Gumbo4Pamela J. McShane5Julie V. Philley6Department of Pulmonary Immunology, University of Texas at Tyler, Tyler, Texas, USA; Department of Immunology, UT Southwestern Medical Center, Dallas, Texas, USA; Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, Texas, USA; Corresponding author. Mailing address: Department of Pulmonary Immunology, University of Texas Health Centre, 11937 US Highway 271, Tyler, TX 75708, USA. Tel.: +1 903 877 7684; fax: +1 903 877 7684.Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USADivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USADepartment of Pulmonary Immunology, University of Texas at Tyler, Tyler, Texas, USAQuantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USASection of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USASection of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USAABSTRACT: Objectives: The aim of this study was to determine and compare the efficacy of drugs to treat Mycobacterium kansasii (Mkn) pulmonary disease by performing minimum inhibitory concentration (MIC) determination and time–kill studies. Methods: We determined the MICs to 13 drugs against the Mkn standard laboratory strain ATCC 12478 and 20 clinical isolates and performed time–kill studies with 18 drugs from different classes using the standard laboratory strain of Mkn. The β-lactam antibiotics were tested with or without the combination of the β-lactamase inhibitor avibactam. An inhibitory sigmoid Emax model was used to describe the relationship between drug concentrations and bacterial burden. Results: Among the 13 tested drugs in the MIC experiments, the lowest MIC was recorded for bedaquiline. Among the 18 drugs used in the time–kill studies, maximum kill with cefdinir, tebipenem, clarithromycin, azithromycin, moxifloxacin, levofloxacin, tedizolid, bedaquiline, pretomanid and telacebac was greater than that for some of the drugs (isoniazid, rifampicin and ethambutol) used in standard combination therapy. Conclusion: We report preclinical data on the efficacy and potency of drugs that can potentially be repurposed to create a safe, effective and likely shorter-duration regimen for the treatment of Mkn pulmonary disease.http://www.sciencedirect.com/science/article/pii/S2213716521002848Nontuberculous mycobacteriaMycobacterium kansasiiRepurposed drugsEfficacy |
| spellingShingle | Shashikant Srivastava Jotam G. Pasipanodya Scott K. Heysell Gunavanthi D. Boorgula Tawanda Gumbo Pamela J. McShane Julie V. Philley An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease Journal of Global Antimicrobial Resistance Nontuberculous mycobacteria Mycobacterium kansasii Repurposed drugs Efficacy |
| title | An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease |
| title_full | An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease |
| title_fullStr | An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease |
| title_full_unstemmed | An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease |
| title_short | An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease |
| title_sort | overview of drugs for the treatment of mycobacterium kansasii pulmonary disease |
| topic | Nontuberculous mycobacteria Mycobacterium kansasii Repurposed drugs Efficacy |
| url | http://www.sciencedirect.com/science/article/pii/S2213716521002848 |
| work_keys_str_mv | AT shashikantsrivastava anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT jotamgpasipanodya anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT scottkheysell anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT gunavanthidboorgula anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT tawandagumbo anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT pamelajmcshane anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT julievphilley anoverviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT shashikantsrivastava overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT jotamgpasipanodya overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT scottkheysell overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT gunavanthidboorgula overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT tawandagumbo overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT pamelajmcshane overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease AT julievphilley overviewofdrugsforthetreatmentofmycobacteriumkansasiipulmonarydisease |